聯化科技(002250.SZ):2025年公司預計醫藥業務將實現一定增長
格隆匯5月27日丨聯化科技(002250.SZ)於近期投資者關係活動表示,公司醫藥業務按計劃逐步推進,2025年,公司預計醫藥業務將實現一定增長。基於聚焦“大客户”的戰略,當前合作方為以歐洲藥企為主的全球醫藥行業領軍企業。在持續深化既有戰略伙伴關係的基礎上,公司同步推進新客户開發、研發實力強化及技術儲備擴充三大核心工作。產能佈局方面,通過科學規劃生產基地建設,已啟動新醫藥車間投資項目,為後續業務擴展提供基礎設施保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.